Seronegative HIV-1 Infection: a Review of the Literature

Spivak, Adam M; Sydnor, Emily RM; Blankson, Joel N; Gallant, Joel E

Disclosures

AIDS. 2010;24(10):1407-1414. 

In This Article

Abstract and Introduction

Abstract

HIV-1-specific antibodies can be detected in HIV-1-positive patients within weeks of primary infection. Rare cases have been reported of patients who are persistently seronegative despite evidence of HIV-1 infection. We present a retrospective review of the clinical, virologic and immunologic characteristics of 25 persistently seronegative patients whose cases have been published to date and postulate a biologic mechanism for this phenomenon.

Introduction

In 1985, the US Food and Drug Administration[1] approved the first diagnostic test for HIV-1, an ELISA that detected the presence of antibodies to viral antigens in the serum. Fourth-generation ELISAs that simultaneously detect HIV-1 antibodies and p24 antigen have been developed over the last decade and are now in clinical use for HIV-1 screening in most countries.[2–4] Specimens deemed positive by ELISA should be confirmed by supplemental testing algorithms employing either alternative format screening assays, western blot, immunofloresence assays or a test to detect HIV RNA according to current Centers for Disease Control and Prevention recommendations.[5] The performance characteristics of this testing strategy have been extensively evaluated,[6,7] and with a sensitivity and specificity greater than 99%,[8–10] it has proven to be one of the most reliable and accurate diagnostic tests in clinical medicine.

Patients exposed to HIV-1 typically develop HIV-1-specific antibodies within several weeks of primary infection.[11] Falsely negative screening HIV-1 antibody tests have most often been attributed to a 'window period' prior to the development of an HIV-1-specific antibody response or infection with HIV-2 or nonclade B HIV-1.[12–17] Several other less common phenomena can lead to falsely negative HIV-1 screening tests. In several case reports, patients treated with HAART very early in the course of disease did not develop a full HIV-1 antibody response, possibly due to HAART-induced virologic suppression and subsequent lack of antigen.[18,19] Another case report[20] describes a patient whose HIV-1 antibodies became undetectable after treatment with HAART and mycophenolate mofetil and returned once these treatments were stopped. In 2005, a case report[21] was published describing a patient with common variable immunodeficiency who lacked HIV antibodies over a 10-month period but had repeatedly detectable HIV-1 viral loads as high as 300 000 copies per milliliter. In rare cases, HIV-1-infected patients who are not receiving antiretroviral therapy (ART) or immunosuppressive medications have demonstrated persistent lack of humoral immunity to HIV-1.[22–41] These patients tend to present with severe immunodeficiency, likely due to a combination of negative antibody-based screening tests that delay diagnosis as well as a tendency toward rapid disease progression.

Over one million people are estimated to be living with HIV-1 in the United States, and more than 16 million people are tested for HIV-1 annually.[5] According to United Nations Programme on HIV/AIDS[2] epidemiologic data, in 2008, there were 33.4 million people living with HIV/AIDS worldwide and 2.7 million incident infections. Since HIV-1 was first recognized, however, there have been only 25 published case reports of patients with confirmed HIV-1 infection who do not have detectable HIV-1 antibodies. We describe here the clinical, virologic and immunologic characteristics of these patients with seronegative HIV-1 infection.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....